1. Randriamboavonjy, V. Badenhoop K, Schmidt H., Geisslinger G., Fisslthaler B., Fleming I.
The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes.
Basic Res Cardiol. 2009 Jan 12.
2. Reddy KR, Nelson DR, Zeuzem S.
Ribavirin: Current role int he optimal clinical management of chronic hepatitis C.
J Hepatol. 2008 Dec. 3 (Epub ahead of print)
3. Soriano V. Peters MG, Zeuzem S.
New therapies for hepatitis C virus infection.
Clin Infect Dis. 2009 Feb 1;48(3):313-20
4. Sroczynski G., Esteban E., Conrads-Frank A., Schwarzer R., Mühlberger N., Wright D., Zeuzem S., Siebert U.
Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection.
Eur J Public Health. 2009 Feb. 5 (Epub ahead of a print)
5. Meyer C., Brieger A., Plotz G., Weber N., Passmann S., Dingermann T., Zeuzem S., Trojan J., Marschalek R.
An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family.
Clin Cancer Res. 2009 Feb 1;15(3):762-9
6. Kronenberger B., Zeuzem S.
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Curr Gastroenterol Rep. 2009 Feb; 11(1):15-21
7. von Wagner M., Zeuzem S.
Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients.
Dtsch Med Wochenschr. 2009 Feb;134(6):255-8
8. Welker M.W., Zeuzem S.
Occult hepatitis C: how convincing are the current data?
Hepatology. 2009 Feb;49(2):665-75
9. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U.
HCV-related burden of disease in Europe: a systematic assessment of invidence, prevalence, morbidity, an mortality
BMC Public Health. 2009 Jan 22;9(1):34
10. Hofmann WP, Soriano V., Zeuzem S.
Antiviral combination therapy of treatment of chronic hepatitis B, hepatitis C and human immunodeficiency virus infection
Handb Exp Pharmacol. 2009;(189):321-46
11. Badenhoop K., Kahles H.,Seidl C., Kordonouri O., Lopez ER, Walter M., Rosinger S., Ziegler S., Ziegler A., Böhm B.O., Diabetes Genetics Consortium
MHC-environment interactions leading to type 1 diabetes: feasibility of an analysis of HLA DR-DQ alleles in relation to manifestation periods and dates of birth
Diabetes Obes Metab. 2009 Feb;11 Suppl 1:88-91
12. Kahles H., Kordonouri O., Ramos Lopez E., Walter M., Rosinger S., Boehm B.O., Badenhoop K., Seidl C., Ziegler A., Diabetes Genetics Consortium
Mating in parents of type 1 diabetes families as a function of the HLA DR-DQ haplotype.
Diabetes Obes Metab. 2009 Feb;11 Suppl. 1:84-7
13. Friedrich-Rust M., Theobald J., Zeuzem S., Bojunga J.
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
J Viral Hepat. 2009 Mar;16(3):168-77
14. Patel K., Benhamou Y., Yoshida E.M., Kaita K.D., Zeuzem S., Torbenson M., Pulkstenis E., Subramanian G.M., McHutchinson J.G.
An indepentent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE an FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
J Viral Hepat. 2009 Mar:16 (3):178-86
15. Reusch J., Ackermann H., Badenhoop K.
Cyclic changes of vitamin D and PTH are Primarily Regulated by Solar Radiation: 5-Year Analysis of a German (50 degrees N) Population.
Horm Metab Res 2009 Feb 24.
16. Hofmann W.P., Zeuzem S.
Advanced chronic hepatitis C: How to handle if you cannot halt?
Hepatology. 2009 Apr;49(4):1385-7 (pubMed in process)
17. Akoglu B., Kriener S., Martens S., Herrmann E., Hofmann W.P., Milovic V., Zeuzem S., Faust D.
Interleukin-2 in CD 8+ T cells correlates with Banff score during organ rejection in liver transplant recipients.
Clin Exp Med. 2009 Mar 19 (epub ahead of print)
18. Pachiadakis I., Chokshi S., Cooksley H., Farmakiotis D., Sarrazin C., Zeuzem S., Michalak TI, Naoumov NV
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dentritic cell functions.
Clin Immunol. 2009 Mar 19 (Epub ahead of print)
19. Zeuzem S., Gane E., Liaw YF., Lim SG., Dibisceglie A., Buti M., Chutaputti A., Rasenack J., Hou J., O’Brien C., Nguyen TT, Jia J., Poynard T., Belanger B., Bao W., Naounmov NV.
Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatis B.
J Hepatol. 2009 Feb 12. (Epub ahead of print)
20. Boehncke S., Poettgen K., Maser-Gluth C., Reusch J., Boehncke WH, Badenhoop K.
Endurance capabilities of triathlon competitors with type 1 diabetes mellitus.
Dtsch Med. Wochenschr. 2009 Apr;134(14):677-82. Epub 2009 Mar 24. German.
21. Vogl TJ., Zeuzem S., Zangos S., Hammerstingl R.
Magnetic resonance cholangiopancreatography (MRCP) from a radiological and gastroenterological perspective.
Dtsch. Med. Wochenschr. 2009 May;134(19):1011-4. Epub 2009 Apr 28. German.
22. Hezodé C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., Bronowicki JP., Bourlière M., Gharakhanian S., Bengtsson L., McNair L., George S., Kieffer T., Kwong A., Kauffman RS., Alam J., Pawlotsky JM., Zeuzem S., PROVE2 Study Team
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
N Engl J. Med. 2009 Apr 30;360(18):1839-50
23. Giacometti R., Kronberg F., Biondi R.M., Passeron S.
Catalytic isoforms Tpk1 and Tpk2 of Candida albicans PKA have non-redundant roles in stress response and glycogen storage.
Yeast. 2009 May;26(5):273-85
24. Randriamboavonjy V., Badenhoop K., Schmidt H., Geisslinger G., Fisslthaler B., Fleming I.
The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes.
Basic Res Cardiol. 2009 May;104(3):333-40. Epub 2009 Jan 12
25. Ramos-Lopez E., Scholten F., Aminkeng F., Wild C., Kalhes H., Seidl C., Tonn T., Van der Auwera B., Badenhoop K.
Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA-C1 ligand binding.
Tissue Antigens. 2009 Apr 8.
26. Friedrich-Rust M., Zeuzem S.
Reproducibility and limitations of transient elastography.
Liver Int. 2009 May:29(5):619-20
Low density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.
Infect Genet Evol. 2009 May 13
28. Hirche T.O., Hirche H., Jungblut S., Stern M., Wagner T.O., Wiedemann B.; on behalf of the German CFQA Group
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis.
J Cyst Fibros. 2009 May 5 (Epub ahead of a print)
29. Brück P., Bartsch W., Penna-Martinez M., Kahles H., Seidl C., Böhme A., Badenhoop K., Ramos-Lopez E.
Polymorphism of CXCR3-binding chemokines in type 1 diabetes.
Hum Immunol. 2009 May 3.
30. Neumann A.U., Pianko S., Zeuzem S., Yoshida E.M., Benhamou Y., Mishan M., McHutchison J.G., Pulkstenis E., Mani Subramanian G.
Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.
J. Hepatol. 2009 Jul:51(1)21-8
31. Penna-Martinez M., Ramos-Lopez E., Stern J., Hinsch N., Hansmann M.L., Selkinski I., Grünwald f., Vorländer C., Wahl R.A., Bechstein W.O., Zeuzem S., Holzer K., Badenhoop K.
Vitamin D receptor polymorphisms in differentiated thyroid carcinoma.
Thyroid. 2009 Jun;:19(6):623-8
32. Halangk J., Berg T., Neumann K., Sarrazin C., Hinrichsen H., Fitz C., Puhl G., Mueller T., Neuhaus P., Wiedenmann B., Witt H.
Evaluation of angiotensinogen c.1-44G>A and p. M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies.
Genet Test Mol Biomarkers. 2009 Jun;3(3):407-14
33. Friedrich-Rust M., Müller C., Winckler A., Kriener S., Herrmann E., Holtmeier J., Poynard T., Vogl T.J., Zeuzem S., Hammerstingl R., Sarrazin C.
Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy and Serum Markers.
J Clin Gastroenterol. 2009 Jul 2. (Epub ahead of print)
34. Kronenberger B., Zeuzem S.
Occludin a new hcv entry factor: Is the list of essential hepatitis c virus receptors complete?
Gastroenterology. 2009 Jun 26. (Epub ahead of print)
35. Wedemeyer H., Schuller E., Schlaphoff V., Stauber R.E., Wiegand J., Schiefke I., Firbas C.,Jilma B., Thursz M., Zeuzem S., Hofmann W.P., Hinrichsen H., Tauber E., Manns M.P., Klade C.S.
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Vaccine. 2009 Jun 23. (Epub ahead of print)
36. Berg T., Weich V., Teuber G., Klinker H.,Möller B., Raenack J., Hinrichsen H., Gerlach T., Spengler U., Buggisch P., Balk H., Zankel M., Neumann K., Sarrazin C., Zeuzem S.
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type1-infected patients.
Hepatology. 2009 Apr 6. (Epub ahead of print)
37. Dietrich C.F.,Ignee A., Barreiros A.P., Schreiber-Dietrich D., Sienz M., Bojunga J., Braden B.
Contrast-enhanced ultrasound for Imaging of Adrenal Masses.
Ultraschall Med. 2009 Apr 28. (Epub ahead of print)
38. Kullmann F., Hollerbach S., Dollinger M. M., Harder J., Fuchs M., Messmann H., Trojan J., Gäbele E., Hinke A., Hollerbach C., Endlicher E.
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer a multicentre phase II study.
Br J Cancer. 2009 Apr 7:100(7):1032-6. Epub 2009 Mar 17.
39. Stroba A., Schaeffer F., Hindie V., Lopez-Garcia L., Adrian I., Frohner W., Hartmann R.W., Biondi R.M., Engel M.
3,5 Diphenylpent-2-enoic Acids as Allosteric Activators of the Protein Kinase PDK1:Structure-Activity Relationships and Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-Targeting Compounds (dagger) PDB code of 2Z with PDK1: 3HRF.
J Med Chem. 2009 Jul 17. (Epub ahead of print)
40. Albert J.G., Lübbert C., Surow A., Zeuzem S.
Small bowel diverticula – unknown disease.
Z Gastroenterol. 2009 Jul;47(7):674-81. Epub 2009 Jul 15. German.
41. Albert J.G., Gittinger F.S., Hainz M., Lübbert C.
In disguise as an acute flare: an unusual differential diagnosis of Crohn’s disease.
Gut. 2009 Jun; 58(6):742, 832.
42. Sroczynski G., Esteban E., Conrads-Frank A., Schwarzer R., Mühlberger N., Wright D., Zeuzem S., Siebert U.
Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
J Viral Hepat. 2009 Jul 28. (Epub ahead of print)
43. Zeuzem S.
Forewarned is forearmed.
J. Hepatol. 2009 Jul 2. (Epub ahead of print)
44. Marcellin P., Bonino F., Lau GK, Farci P., Yurdaydin C., Piratvisuth T., Jin R., Gurel S., Lu Z.M., Wu J., Popescu M., Hadziyannis S., Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Gastroenterology. 2009 Jun; 136(7):2169-2179.e1-4
45. Hofmann W.P., Zeuzem S.
Hepatitis C: new therapeutic strategies needed for advance disease.
Nat Rev Gastroenterol. Hepatol. 2009 Jun;6(6):325-7
46. Zimmer V., Feiden W., Becker G., Zimmer A., Reith W., Raedle J., Lammert F., Zeuzem S., Hirano M., Menges M.
Absence of the interstitial cell of Cajal network in mitochondrial neurogastrointestinal encephalomyopathy.
Neurogastroenterol Motil. 2009 Jun;21(6):627-31
47. Gottlieb J., Ballmann M., von Mallinckrodt C., Staab D., Smaczny C., Simon A., Welte T., Wagner T.O.
Lung transplatation in cystic fibrosis - a position paper.
Pneumologie. 2009 Aug;63(8):451-60. Epub 2009 Aug 7. German.
48. Deterding K., Wiegand J., Grüner N., Hahn A., Jäckel E., Jung M.C., Buggisch P., Galle P., Berg T., Hinrichsen H., Potthoff A., Zeuzem S., Cornberg M., Manns M., Wedemeyer H.
The german hep-net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Z Gastroenterol. 2009 Jun;47(6):531-40
49. Preiss J.C., Blumenstein I., Zeuzem S., Zeitz M.
The state of health care and health care paths in inflammatory bowel disease (Crohn’s disease and ulcerative colitis).
Z Gastroenterol. 2009 Jun;47(6):529-30
50. Friedrich-Rust M., Wunder K., Kriener s., Sotoudeh F., Richter S., Bojunga J. Herrmann E., Poynard T., Dietrich CF, Vermehren J., Zeuzem S., Sarrazin C
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography.
Radiology, 2009 Aug;252(2):595 -604
51. Dettori R., Sonzogni S., Meyer L., Lopez-Garcia L.A., Morrice N.A., Zeuzem S., Engel M., Piiper A., Neimanis S., Frodin M., Biondi R.M.
Regulation of the interaction between the protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase, the 3-phosphoinositide-dependent protein kinase 1 (PDK 1).
J. Biol Chem.2009 Sept 1. (Epub ahead of print)
52. Hindie V., Stroba A., Zhang H., Lopez-Garcia L.A., Idrissova L., Zeuzem S., Hirschberg D., Schaeffer F., Jørgensen T.J., Engel M., Alzari P.M., Biondi R.M.
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK 1.
Nat Chem Biol. 2009 Aug 30. (Epub ahead of Print)
53. Mihm U., Hofmann W.P., Welsch C., Polta A., Lengauer T., Zeuzem S., Sarrazin C., Herrmann E.
Effect of ribavirin on the frequency Of RNase L Cleavage sites within the hepatitis C viral genome.
J Viral Hepat. 2009 Sep 15 (Epub ahead of print)
54. Buster E.H., Hansen B.E., Lau G.K., Piratvisuth T., Zeuzem S., Steyerberg E.W., Janssen H.L.
Factors that predict Response of Patients with Hepatitis B e Antigen-Positive Chronic Hepatits B to Peginterferon-alpha.
Gastroenterology. 2009 Sep 5. (Epub ahead of print)
55. Friedrich-Rust M., Schwarz A., Ong M., Dries V., Schirmacher P., Herrmann E., Samaras P., Bojunga J., Bohle R.M., Zeuzem S., Sarrazin C.
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
Ultraschall Med. 2009 Oct;30(5):478-84. Epub 2009 Oct 7.
56. Lange C.M., Hofmann W.P., Kriener S., Jacobi V., Welsch C., Just-Nuebling G., Zeuzem S.
Primary actinomycosis of the liver mimicking malignancy.
Z Gastroenterol. 2009 Oct;47(10):1062-4. Epub 2009 Oct 6.
57. Blumenstein I., Bock H., Zosel C., Dignass A.U., Hartmann F., Zeuzem S., Stein J.M., Schroeder O.
Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial.
Z Gastroenterol. 2009 Oct;47(10):1045-51.Epub 2009 Oct 6. German.
58. Waidmann O., Pleli T., Dvorak K., Baehr C., Mondorf U., Plotz G. Biondi R.M., Zeuzem S., Piiper A.
Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products.
J Biol Chem. 2009 Sep 29. (Epub ahead of print)
59. Lukasiewicz E., Gorfine M., Freedman L.S., Pawlotsky J.M., Schalm S.W., Ferrari C., Zeuzem S., Neumann A.U.; for the DITTO-HCV Study Group
Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.
J Viral Hepat. 2009 Sep 25. (Epub ahead of print)
60. Susser S., Welsch C., Wang Y., Zettler M., Domingues F.S., Karey U., Hughes E., Ralston R., Tong X., Herrmann E., Zeuzem S., Sarrazin C.
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Hepatology. 2009 Aug 4. (epub ahead of print)
61. Lange C.M., Tran T.Y., Farnik H., Jungblut S., Born T., Wagner T.O., Hirche T.O.
Increased frequency of regulatory T Cells an selection of highly potent CD62L+cells during treatment of human lung transplant recipients with rapamycin.
Transpl Int. 2009 Oct 5. (Epub ahead of print)
62. Welsch, C., Zeuzem S.
RNA-Binding Activity of Hepatitis C Virus NS4B: A Novel Target for Small Molecule Inhibitors.
Gastroenterology. 2009 Oct 27. (Epub ahead of print)
63. Farnik H., El-Duweik J., Welsch C., Sarrazin C., Lötsch J., Zeuzem S., Geisslinger G., Schmidt H.
Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) an telaprevir (VX 950) in human plasma by LC-MS/MS).
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 14.
64. Friedrich-Rust M., Sperber A., Holzer K., Diener J., Grünwald F., Badenhoop K., Weber S., Kriener S., Herrmann E., Bechstein W.O., Zeuzem S., Bojunga J.
Real-time Elastography and Contrast-Enhanced Ultrasound for the Assessment of Thyroid Nodules.
Exp Clin Endocrinol Diabetes 2009
65. Zachou K., Yurdaydin C., Drebber U., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., Gurel S., Zeuzem S., Bozkaya H., Schlapphoff V., Dienes H.P., Bock T.C., Manns M.P., Wedemeyer H.,; for HIDT-1 Study Group
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Liver Int. 2009 Oct 15. (Epub ahead of print)
66. Peveling-Oberhag J., Zeuzem S., Hofmann W.P.
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.
Med Microbiol Immunol. 2009 Nov 10. (Epub ahead of print)
67. Dauletbaev N., Fischer P., Aulbach B., Gross J., Kusche W., Thyroff-Friesinger U., Wagner T.O., Bargon J.
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis.
Eur J Med Res. 2009 Aug 12;14(8):352-8
68. Lange C.M., Bojunga J., Hofmann W.P., Wunder K., Mihm U., Zeuzem S., Sarrazin C.
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
Hepatology. 2009 Dec;50(6):2001-6
69. Rabenhorst, U., Beinoraviciute-Kellner R., Brezniceeanu M.L., Joos S., Devens F., Lichter P., Rieker R.J., Trojan J., Chung H.J., Levens D.L., Zörnig M.
Overexpression for the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.
Hepatology. 2009 Oct;50(4):1121-9
70. Casper M., Plotz G., Juengling B., Trojan J., Lammert F., Raedle J.
Adenoma Development in a Patient with MUTYH-Associated Polyposis (MAP): New Insights into the Natural Course of Polyp Development.
Dig Dis Sci. 2009 Aug 12. (Epub ahead of print)
71. Zeuzem S.
Do Differences in Pegylation of Interferon Alfa Matter?
Gastroenterology. 2009 Nov. 20 (Epub ahead of print)
72. Penna-Martinez M., Ramos-Lopez E., Robbers I., Kahles H., Hahner S., Willenberg H., Reisch N., Seidl C., Segni M., Badenhoop K.
The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves‘ disease, Hashimoto’s thyroiditis and Addison’s disease.
BMC Med Genet. 2009 Dec 4;10(1):126. (Epub ahead of print)
73. van Boemmel F., de Man R.A., Wedemeyer H., Deterding K., Petersen J., Buggisch P., Erhardt A., Hüppe D., Stein K., Trojan J., Sarrazin C., Böcher W.O., Spengler U., Wasmuth H.E., Reinders J.G., Möller B., Rhode P., Feucht H.H., Wiedenmann B., Berg T.
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
Hepatology ..(Epub ahead of print)
Stand Dezember 2009
Nach oben
Drucken
Versenden